01—Abstract
Summary
Summary of the 10-Q filed July 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation (SYK) reported strong financial performance for the second quarter and first half of 2024, demonstrating robust top-line growth and improved profitability.
Net sales increased by 8.5% to $5.42 billiona for the quarter and 9.1% to $10.67 billion for the first half, driven by solid unit volume increases across both the MedSurg and Neurotechnology and Orthopaedics and Spine segments. This growth was achieved despite ongoing macroeconomic challenges such as inflation and supply chain disruptions. Profitability metrics also showed positive trends.
Gross profit margin remained strong, and operating income saw significant increases, particularly in the MedSurg and Neurotechnology segment. Diluted earnings per share (EPS) rose to $2.14b for the quarter and $4.19 for the six-month period, reflecting the company's operational efficiency and strategic execution. Stryker's balance sheet remains healthy, with ample liquidity to support ongoing operations and strategic initiatives, including acquisitions.
02—Key points
Key Highlights
- Net sales increased by 8.5% year-over-year to $5.42 billion in Q2 2024 and 9.1% to $10.67 billion for the first six months of 2024.
- Organic sales growth (excluding currency, acquisitions, and divestitures) was strong at 9.4% for Q2 and 9.8% for the first half of the year.
- Gross profit margin was 63.0% in Q2 2024, a slight decrease from 63.7% in Q2 2023, primarily due to higher manufacturing and supply chain costs.
- Diluted earnings per share (EPS) increased to $2.14 in Q2 2024, up from $1.93 in the prior year's quarter, and $4.19 for the first six months, up from $3.47.
- The MedSurg and Neurotechnology segment showed robust growth, with net sales up 9.0% in Q2, while Orthopaedics and Spine saw a 7.9% increase.
- The company acquired SERF SAS for $244 million in Q1 2024, strengthening its Joint Replacement business.
- Operating income increased to $1,051 million in Q2 2024, up from $965 million in the prior year's quarter, with operating margin improving to 19.4% from 19.3%.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Stryker Corp kept $0.15.
- Revenue$5.42B100.0%
- Cost of revenue−$2.01B37.0%
- Gross profit$3.42B63.0%
- Operating costs−$2.37B43.6%
- Operating income$1.05B19.4%
- Interest, other & tax−$226.0M4.2%
- Net income$825.0M15.2%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 31, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $5.42B$5.00B | +8.5% |
| Cost of Revenue | $2.01B$1.81B | +10.5% |
| Gross Profit | $3.42B$3.18B | +7.4% |
| R&D Expenses | $363.00M$346.00M | +4.9% |
| SG&A Expenses | $1.83B$1.71B | +7.1% |
| Operating Expenses | $2.37B$2.22B | +6.7% |
| Operating Income | $1.05B$965.00M | +8.9% |
| Interest Expense | $96.00M— | — |
| Net Income | $825.00M$738.00M | +11.8% |
| EPS (Basic) | $2.17$1.95 | +11.3% |
| EPS (Diluted) | $2.14$1.93 | +10.9% |
| Shares Outstanding (Basic) | 381.00M379.70M | +0.3% |
| Shares Outstanding (Diluted) | 385.40M383.90M | +0.4% |
05—Questions
Frequently Asked Questions
What was the primary driver of Stryker's sales growth in Q2 2024?
Stryker's sales growth was primarily driven by an increase in unit volume across both its MedSurg and Neurotechnology and Orthopaedics and Spine segments. This indicates strong demand for its products despite broader economic headwinds.
How did Stryker manage its profitability in the face of rising costs?
While gross profit margin saw a slight decrease due to higher manufacturing and supply chain costs, Stryker managed to maintain strong operating income and improve its operating margin for the six-month period. This was achieved through disciplined expense management, particularly in SG&A, and favorable sales pricing and volume contributions.
What is Stryker's current financial position and liquidity?
Stryker maintains a strong financial position with $1.874 billion in cash and cash equivalents as of June 30, 2024. Current assets significantly exceeded current liabilities, indicating healthy short-term liquidity. The company has access to various funding sources, including operating cash flow and credit facilities, to support its needs.
What impact did acquisitions have on Stryker's results in this quarter?
The acquisition of SERF SAS in March 2024 contributed to the growth in the Orthopaedics and Spine segment. The company also noted the impact of acquisitions and divestitures in its constant currency sales growth calculations, which were minimal for the reported periods.
06—Continue